NCT05303740已完成不适用
Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study
Feng Wang1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2019年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Esophageal cancer diagnosed pathologically or clinically
- •Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment
排除标准
- 未提供
研究组 & 干预措施
Anlotinib
干预措施: Anlotinib (Drug)
结局指标
主要结局
PFS
时间窗: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Progression Free Survival
次要结局
- OS(From date of admission until the date of death from any cause, assessed up to 24 months)
研究者
Feng Wang
Chief physician
The First Affiliated Hospital of Zhengzhou University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Sutent + Taxol for Advanced Esophageal CancerEsophageal CancerNCT00730353Hoosier Cancer Research Network28
已完成
不适用
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)NSCLCNCT04871997Qian Chu373
已完成
1 期
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT02645864Peking University12
Unknown
1 期
First-line Combination Treatment Based on AnlotinibAdvanced StageLung CancerNCT03628521Shanghai Chest Hospital80
已完成
2 期
Combination of Toripalimab and Chemoradiotherapy in Esophageal CancerUnresectable Esophageal CancerNCT04005170Mian XI42